Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment
Open Access
- 18 May 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (12), 1687-1691
- https://doi.org/10.1038/sj.bjc.6605697
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancerAnti-Cancer Drugs, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- Capecitabine Monotherapy for Recurrent and Metastatic Nasopharyngeal CancerJapanese Journal of Clinical Oncology, 2008
- Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck regionHead & Neck, 2006
- Capecitabine: A reviewClinical Therapeutics, 2005
- Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neckRadiotherapy and Oncology, 2004
- Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual dataThe Lancet, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Head and Neck CancerThe New England Journal of Medicine, 1993
- Chemotherapy in Head and Neck CancerThe New England Journal of Medicine, 1983